Berberine

If you have prescription access and a clinical indication (type-2 diabetes, pre-diabetes with risk factors), metformin is first-line — it's cheaper ($4/month generic), longer track record, FDA-approved, and the longevity evidence base is larger. Berberine is the right answer when you DON'T have prescription access, are at the metabolic-syndrome / pre-diabetes stage where a doctor won't prescribe yet, or are stacking for longevity rather than treating disease. The Yin 2008 head-to-head trial showed berberine 500 mg 3×/day equivalent to metformin 1,500 mg/day on HbA1c, fasting glucose, and postprandial glucose in T2D — but "equivalent in one trial" is not "interchangeable." Many longevity-focused users actually take both at reduced doses for additive AMPK activation, under clinician oversight.

Dihydroberberine is the partially reduced metabolite — what gut bacteria convert berberine HCl into before absorption. DHB supplements claim 3-5× higher bioavailability, which means 100 mg DHB roughly equals 500 mg HCl in plasma exposure. The catch is that the 30+ human RCTs were almost entirely run on HCl, not DHB — so the evidence base sits with the cheap form. Practical answer: start with HCl (500 mg 2-3× daily, ~$15/month). If GI side effects are intolerable or you don't respond, switch to DHB (~$45/month) for the better-absorbed + better-tolerated profile. DHB is the right form if cost isn't the constraint; HCl is the right form if it is.

Two reasons. First, the postprandial glucose blunting — berberine's GLUT4-translocation effect happens when it's circulating during a meal, so timing the dose with food maximises the per-meal glucose-spike reduction. Second, food slows gastric emptying, which gives berberine longer contact time with the intestinal wall (where the gut-microbiome mechanism plays out) and partially mitigates the loose-stool side effect. The clinical protocol is 500 mg within 30 minutes before or after breakfast, lunch, and dinner. Skipping a meal? Skip that dose — there's no meaningful benefit to taking berberine without food.

Ramp first, then split, then switch form before quitting. Ramp protocol: 500 mg once daily for 1 week → 500 mg twice daily for 1 week → 500 mg three times daily ongoing. If you're already at 1,500 mg/day and struggling, drop back to 1,000 mg (twice daily) for 2 weeks before re-trying the full dose. Split protocol: never take more than 500 mg in a single dose — the loose-stool effect scales with peak luminal concentration, not total daily intake. Form switch: phytosome or DHB formulations cut the GI burden ~50% because more of the dose enters circulation rather than sitting in the gut. About 5-10% of users are simply non-tolerators and should look at inositol (for PCOS / insulin sensitivity) or alpha-lipoic acid as alternatives.

Only with clinician oversight, and not as a casual stack. The two share the AMPK + Complex I mechanism, so the effects are additive on glucose-lowering — which means additive hypoglycemia risk. The Pérez-Rubio 2013 trial combined metformin + berberine in metabolic-syndrome subjects with monitoring and saw improved outcomes vs metformin alone, but doses were titrated. Practical answer: don't add berberine on top of a stable metformin dose without your endocrinologist adjusting metformin downward. The right framing is "replace some metformin with some berberine," not "layer berberine on top."

The Wei 2012 PCOS trial (PMID 22735456) ran 500 mg 3×/day for 12 weeks and matched metformin's effects on insulin sensitivity, BMI, waist-to-hip ratio, and ovulation frequency — with a more favorable lipid profile. Standard PCOS protocol: 500 mg with each main meal (3×/day, 1,500 mg total) for 12 weeks minimum, then reassess. Common stacks: berberine + myo-inositol/d-chiro-inositol 40:1 ratio (the Genazzani protocol) hits both AMPK and IP3 signaling, with stronger pregnancy outcomes in trials than either alone. Coordinate with your reproductive endocrinologist if you're trying to conceive — berberine is contraindicated once pregnancy is confirmed.

Yes by mechanism, mostly inferred by outcome. AMPK is one of the four conserved aging pathways (Kennedy 2014, López-Otín hallmarks-of-aging framework) — pharmacologically activating it extends lifespan in worms, flies, and mice. In humans we don't have direct lifespan trials (we won't for decades), so the evidence is one rung down: berberine reproducibly improves the biomarkers that predict longevity (HbA1c, fasting insulin, triglycerides, LDL, visceral adiposity, hsCRP). The longevity community treats berberine as a metformin-class lever — same mechanism, same biomarker profile, no prescription required. Standard longevity dose is 500 mg 2×/day with the two largest meals, often cycled 12 weeks on / 4 weeks off out of caution rather than data.

Modestly and indirectly. The Lan 2015 meta showed 2-4 kg average loss over 12 weeks in metabolic-syndrome populations — mostly visceral fat, not subcutaneous, and concentrated in subjects who started with insulin resistance. If your baseline insulin sensitivity is already good, the weight effect is small. Berberine is not an appetite suppressant and not a GLP-1 agonist substitute (it does indirectly raise GLP-1 via the microbiome, but not at the magnitudes semaglutide produces). Think of it as a metabolic-environment improver: when insulin sensitivity normalises, body composition tends to follow over months. Pair with resistance training and protein intake for the meaningful body-recomposition effect.